Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

14 Apr 2017

• By Joseph Haas

Film x-ray knee joint with arthritis

Related Content

Market Failure? Lower Drug Prices Don't Improve Access In Rheumatoid Arthritis

07 Apr 2017

Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs

27 Jan 2017

Sanofi/Regeneron Choose Access Over Price With Dupixent Launch

28 Mar 2017

Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss

31 Oct 2016

Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

16 Dec 2016

With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled

30 May 2016

Canada First To OK Sanofi/Regeneron’s Sarilumab, But Struggle To Differentiate Looms

01 Feb 2017

Related Companies

Eli Lilly and Company

Incyte Corporation

GSK plc

Johnson & Johnson

Sanofi

Regeneron Pharmaceuticals, Inc.

AbbVie Inc.

Amgen, Inc.

Pfizer Inc.

Additional Topics

Complete Response Letters Pricing Strategies Drug Review Commercial Immune Disorders Inflammation BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.